{
    "hands_on_practices": [
        {
            "introduction": "Many cardiac arrhythmias are caused by reentrant circuits, where an electrical impulse gets trapped in a continuous loop. For this \"short-circuit\" to be sustained, the impulse must take long enough to travel around the loop for the tissue at the starting point to recover its excitability. This exercise  provides a hands-on opportunity to connect fundamental electrophysiological properties—conduction velocity ($CV$) and effective refractory period ($ERP$)—to the minimum physical path length required for reentry, bridging the gap between abstract concepts and concrete anatomical substrates.",
            "id": "4949113",
            "problem": "A macroreentrant cardiac tachycardia occurs when an activation wavefront continuously circulates around an anatomical or functional obstacle. Starting from first principles in cardiac electrophysiology, use the following core definitions and facts to derive the minimal circuit path length needed to sustain reentry. Conduction velocity (CV) is defined as the speed at which the activation wavefront propagates through myocardium, measured in distance per unit time. The effective refractory period (ERP) is defined as the shortest interval after an action potential during which a new propagated response can be elicited. For sustained reentry, the wavefront must traverse the circuit such that, upon its return to the point of origin, the tissue there has recovered excitability.\n\nGiven a scar channel in the ventricle with measured conduction velocity $CV = 0.4\\,\\text{m s}^{-1}$ and effective refractory period $ERP = 200\\,\\text{ms}$, derive an expression for the minimal circuit path length in terms of $CV$ and $ERP$, compute its value, and then interpret the result in clinical terms by explaining whether typical ventricular macroreentry is plausible in a substrate that is approximately $8$ to $10$ centimeters in path length. Express the final numerical answer for the minimal circuit path length in centimeters, and round your answer to three significant figures.",
            "solution": "The problem statement will be validated against the criteria of scientific soundness, well-posedness, completeness, and objectivity.\n\n### Step 1: Extract Givens\n- **Definition 1**: Macroreentrant cardiac tachycardia is described as an activation wavefront continuously circulating around an obstacle.\n- **Definition 2**: Conduction velocity ($CV$) is the speed of wavefront propagation.\n- **Definition 3**: Effective refractory period ($ERP$) is the shortest interval after an action potential during which a new propagated response can be elicited.\n- **Condition for Sustained Reentry**: The wavefront must traverse the circuit such that, upon its return to the point of origin, the tissue there has recovered excitability.\n- **Given Data 1**: A specific measured conduction velocity is $CV = 0.4\\,\\text{m s}^{-1}$.\n- **Given Data 2**: A specific measured effective refractory period is $ERP = 200\\,\\text{ms}$.\n- **Task 1**: Derive an expression for the minimal circuit path length in terms of $CV$ and $ERP$.\n- **Task 2**: Compute the value of this minimal path length.\n- **Task 3**: Interpret the result by comparing it to a typical ventricular macroreentry substrate path length of $8$ to $10$ centimeters.\n- **Output Requirement**: The final numerical answer for the minimal path length must be in centimeters, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Grounding**: The problem is firmly based on fundamental principles of cardiac electrophysiology. The concepts of conduction velocity ($CV$), effective refractory period ($ERP$), and reentry are cornerstones of arrhythmogenesis. The condition for sustained reentry stated in the problem is the correct and universally accepted principle. The provided values, $CV = 0.4\\,\\text{m s}^{-1}$ (representing slowed conduction in diseased tissue) and $ERP = 200\\,\\text{ms}$, are physiologically realistic.\n- **Well-Posed**: The problem is well-posed. It provides all necessary definitions and data ($CV$ and $ERP$) to derive the minimal path length. The question asks for a minimum, which arises naturally from the inequality governing the physical condition, leading to a unique, stable, and meaningful solution.\n- **Objective and Complete**: The problem is stated using clear, objective, and precise terminology. It is self-contained and free of contradictions or missing information.\n- **Realism**: The scenario of a scar-based macroreentry in the ventricle is a common and clinically significant phenomenon. The dimensions provided for comparison ($8$ to $10\\,\\text{cm}$) are consistent with the anatomical scale of the human heart ventricles.\n\n### Step 3: Verdict and Action\nThe problem is valid as it is scientifically sound, well-posed, complete, and objective. A solution will be derived.\n\n### Derivation and Solution\n\nThe fundamental condition for a macroreentrant tachycardia to be sustained is that the time it takes for the activation wavefront to complete one full circuit must be at least as long as the effective refractory period of the tissue at any point in the circuit. If the wavefront returns to its point of origin before the tissue has recovered its excitability (i.e., before the $ERP$ has elapsed), it will encounter refractory tissue and the circuit will terminate.\n\nLet $L$ represent the path length of the reentrant circuit.\nLet $T_{cycle}$ be the time required for the wavefront to traverse the entire circuit once. This is also known as the tachycardia cycle length.\nThe conduction velocity, $CV$, is defined as the distance traveled per unit time. Therefore, the relationship between these quantities is:\n$$CV = \\frac{L}{T_{cycle}}$$\nFrom this, the cycle time can be expressed as:\n$$T_{cycle} = \\frac{L}{CV}$$\nThe condition for sustained reentry is that the cycle time must be greater than or equal to the effective refractory period, $ERP$:\n$$T_{cycle} \\ge ERP$$\nSubstituting the expression for $T_{cycle}$, we get:\n$$\\frac{L}{CV} \\ge ERP$$\nWe are asked to find the minimal circuit path length, which we will denote as $L_{min}$. This minimum length corresponds to the limiting case where the wavefront arrives precisely at the moment the tissue becomes excitable again. This occurs when the inequality becomes an equality:\n$$\\frac{L_{min}}{CV} = ERP$$\nSolving this equation for $L_{min}$ gives the general expression for the minimal path length required to sustain reentry:\n$$L_{min} = CV \\times ERP$$\nThis is the derived expression in terms of $CV$ and $ERP$.\n\nNext, we compute the numerical value for $L_{min}$ using the given data.\nThe given values are:\n$CV = 0.4\\,\\text{m s}^{-1}$\n$ERP = 200\\,\\text{ms}$\n\nTo ensure dimensional consistency, the time unit must be the same for both quantities. We convert milliseconds ($ms$) to seconds ($s$):\n$$ERP = 200\\,\\text{ms} = 200 \\times 10^{-3}\\,\\text{s} = 0.2\\,\\text{s}$$\nNow, we can substitute the numerical values into the expression for $L_{min}$:\n$$L_{min} = (0.4\\,\\text{m s}^{-1}) \\times (0.2\\,\\text{s})$$\n$$L_{min} = 0.08\\,\\text{m}$$\nThe problem requires the final answer to be in centimeters ($cm$). We convert meters ($m$) to centimeters:\n$$L_{min} = 0.08\\,\\text{m} \\times \\frac{100\\,\\text{cm}}{1\\,\\text{m}} = 8\\,\\text{cm}$$\nThe result must be rounded to three significant figures. The value $8$ is written as $8.00$ to indicate this precision.\n$$L_{min} = 8.00\\,\\text{cm}$$\n\nFinally, we interpret this result in clinical terms. The problem asks whether typical ventricular macroreentry is plausible in a substrate with a path length of approximately $8$ to $10$ centimeters. Our calculation shows that the minimal required path length for the given electrophysiological properties ($CV$ and $ERP$) is $8.00\\,\\text{cm}$. Since this calculated minimum falls at the lower bound of the specified typical range ($8$ to $10\\,\\text{cm}$), a substrate of this size is indeed a plausible anatomical basis for sustaining macroreentry. A circuit path of $8.00\\,\\text{cm}$ would be just long enough to permit reentry. A longer path, such as $10\\,\\text{cm}$, would provide an \"excitable gap\"—a segment of recovered tissue ahead of the circulating wavefront—which tends to increase the stability of the arrhythmia. Therefore, the finding is entirely consistent with clinical observations of ventricular tachycardia.",
            "answer": "$$\\boxed{8.00}$$"
        },
        {
            "introduction": "The QT interval on an electrocardiogram is a crucial indicator of ventricular repolarization, but its raw measurement can be misleading as it naturally varies with heart rate. This practice  introduces the essential clinical skill of rate-correcting the QT interval using standard formulas like Bazett's and Fridericia's. By applying these methods, you will learn how to unmask the true risk of developing the life-threatening arrhythmia Torsades de Pointes, a critical step in safely monitoring patients on certain medications.",
            "id": "4949084",
            "problem": "A clinician evaluates a patient who has started a medication known to prolong ventricular repolarization. On a standard twelve-lead electrocardiogram, the measured QT interval is $0.42 \\,\\text{s}$ and the corresponding RR interval is $0.60 \\,\\text{s}$. The objective is to standardize the QT interval to an RR interval of $1.0 \\,\\text{s}$ using two empirically validated rate-correction approaches and then assess the risk for Torsades de Pointes (TdP). The high-risk threshold for TdP will be taken as a corrected QT interval of $0.500 \\,\\text{s}$.\n\nStarting from the fundamental definitions that the QT interval represents ventricular depolarization plus repolarization time, that the RR interval is the time between successive R waves, and that heart rate varies with RR as $HR = \\frac{60}{RR}$ (with $RR$ in seconds and $HR$ in beats per minute), use well-tested rate-correction methodology to map the observed QT at the given RR to the corrected QT at $RR = 1.0 \\,\\text{s}$ by:\n- The Bazett method.\n- The Fridericia method.\n\nThen, using the criterion that TdP risk is present if the corrected QT interval reaches or exceeds $0.500 \\,\\text{s}$, define a risk indicator $R$ as follows:\n- $R = 1$ if either the Bazett-corrected or the Fridericia-corrected QT interval is greater than or equal to $0.500 \\,\\text{s}$.\n- $R = 0$ otherwise.\n\nCompute $R$ using the provided $RR$ and $QT$ values. The final answer must be the single number $R$. No rounding instruction is necessary for this indicator. Do not include units in your final reported value.",
            "solution": "The problem requires the calculation of a risk indicator, $R$, for Torsades de Pointes (TdP) based on a patient's electrocardiogram measurements. The problem has been validated as scientifically sound, well-posed, and containing all necessary information for a unique solution.\n\nThe provided data are:\n- Measured QT interval: $QT_{measured} = 0.42 \\,\\text{s}$\n- Measured RR interval: $RR_{measured} = 0.60 \\,\\text{s}$\n\nThe task is to calculate the rate-corrected QT interval ($QT_c$) using two different methods, Bazett's and Fridericia's, and then to determine the value of the risk indicator $R$. The correction standardizes the QT interval to a heart rate corresponding to an RR interval of $1.0 \\,\\text{s}$.\n\nFirst, we apply the Bazett correction formula, which is defined as:\n$$QT_{c,Bazett} = \\frac{QT_{measured}}{\\sqrt{RR_{measured}}}$$\nThe $RR_{measured}$ must be in units of seconds, which is the case here. Substituting the given values:\n$$QT_{c,Bazett} = \\frac{0.42}{\\sqrt{0.60}}$$\nTo evaluate this expression, we can proceed with a numerical calculation:\n$$QT_{c,Bazett} = \\frac{0.42}{0.774596...} \\approx 0.542219... \\,\\text{s}$$\n\nNext, we apply the Fridericia correction formula, which is defined as:\n$$QT_{c,Fridericia} = \\frac{QT_{measured}}{\\sqrt[3]{RR_{measured}}}$$\nAgain, substituting the given values:\n$$QT_{c,Fridericia} = \\frac{0.42}{\\sqrt[3]{0.60}}$$\nProceeding with a numerical calculation:\n$$QT_{c,Fridericia} = \\frac{0.42}{0.843432...} \\approx 0.498008... \\,\\text{s}$$\n\nThe risk indicator $R$ is defined based on the condition that TdP risk is high if the corrected QT interval is greater than or equal to the threshold of $0.500 \\,\\text{s}$. The definition is:\n- $R = 1$ if $QT_{c,Bazett} \\ge 0.500 \\,\\text{s}$ or $QT_{c,Fridericia} \\ge 0.500 \\,\\text{s}$.\n- $R = 0$ otherwise.\n\nWe must check if either of our calculated $QT_c$ values meets the criterion.\n\nFor the Bazett-corrected value:\nIs $QT_{c,Bazett} \\ge 0.500$?\n$0.542219... \\ge 0.500$. This inequality is true.\n\nFor the Fridericia-corrected value:\nIs $QT_{c,Fridericia} \\ge 0.500$?\n$0.498008... \\ge 0.500$. This inequality is false.\n\nThe condition for $R=1$ is a logical 'OR' (disjunction). We must evaluate the truth of the statement: $(QT_{c,Bazett} \\ge 0.500) \\lor (QT_{c,Fridericia} \\ge 0.500)$.\nSince the first part of this statement, $QT_{c,Bazett} \\ge 0.500$, is true, the entire logical expression is true.\nAccording to the definition provided, if the condition is met for either correction method, the risk indicator $R$ is assigned the value of $1$.\n\nTherefore, the value of the risk indicator is $R = 1$.",
            "answer": "$$\\boxed{1}$$"
        },
        {
            "introduction": "Managing chronic conditions like Atrial Fibrillation extends beyond rhythm control to the prevention of its most serious complications, notably ischemic stroke. However, the primary treatment—anticoagulation—introduces its own risk of major bleeding. This practical exercise  guides you through the evidence-based process of using validated clinical scoring systems, the $\\text{CHA}_2\\text{DS}_2\\text{-VASc}$ and $\\text{HAS-BLED}$ scores, to quantify these competing risks and ultimately calculate the net clinical benefit of therapy, embodying the core of modern, patient-centered decision-making.",
            "id": "4949118",
            "problem": "A patient with Atrial Fibrillation (AF) presents for risk stratification and decision-making regarding initiation of a Direct Oral Anticoagulant (DOAC). The patient is a $74$-year-old female with a history of Congestive Heart Failure (CHF) with left ventricular ejection fraction $35\\%$, medically treated hypertension, type $2$ diabetes mellitus, prior myocardial infarction (vascular disease), and stage $3$ chronic kidney disease with estimated Glomerular Filtration Rate (eGFR) $45\\ \\text{mL}\\cdot \\text{min}^{-1}\\cdot (1.73\\ \\text{m}^2)^{-1}$. She has no prior stroke, transient ischemic attack, or systemic embolism, no prior major bleeding, no labile International Normalized Ratio (INR) because she is not on warfarin, and no concomitant nonsteroidal anti-inflammatory drugs or alcohol misuse.\n\nUse the following well-validated clinical scoring systems and risk calibrations as the foundational base.\n\nDefinitions of the Congestive heart failure, Hypertension, Age, Diabetes, Stroke, Vascular disease, Age, Sex category ($\\text{CHA}_2\\text{DS}_2\\text{-VASc}$) score components:\n- CHF or left ventricular dysfunction: $1$ point.\n- Hypertension: $1$ point.\n- Age $\\geq 75$ years: $2$ points.\n- Diabetes mellitus: $1$ point.\n- Prior stroke, transient ischemic attack, or systemic embolism: $2$ points.\n- Vascular disease (myocardial infarction, peripheral artery disease, or aortic plaque): $1$ point.\n- Age $65$ to $74$ years: $1$ point.\n- Sex category female: $1$ point.\n\nCalibrated annual ischemic stroke risk without anticoagulation by $\\text{CHA}_2\\text{DS}_2\\text{-VASc}$ score (events per $100$ patient-years):\n- Score $0 \\mapsto 0.5$\n- Score $1 \\mapsto 1.0$\n- Score $2 \\mapsto 2.2$\n- Score $3 \\mapsto 3.2$\n- Score $4 \\mapsto 4.0$\n- Score $5 \\mapsto 6.7$\n- Score $6 \\mapsto 9.8$\n\nDefinitions of the Hypertension, Abnormal renal or liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol ($\\text{HAS-BLED}$) bleeding risk score components:\n- Hypertension (systolic blood pressure $>160\\ \\text{mmHg}$ or treated): $1$ point.\n- Abnormal renal function (e.g., eGFR $<60\\ \\text{mL}\\cdot \\text{min}^{-1}\\cdot (1.73\\ \\text{m}^2)^{-1}$) or abnormal liver function: $1$ point each, maximum $2$.\n- Prior stroke: $1$ point.\n- Bleeding history or predisposition: $1$ point.\n- Labile INR: $1$ point.\n- Elderly (age $>65$ years): $1$ point.\n- Drugs predisposing to bleeding (e.g., antiplatelets, nonsteroidal anti-inflammatory drugs) or alcohol misuse: $1$ point each, maximum $2$.\n\nCalibrated annual major bleeding risk without anticoagulation by $\\text{HAS-BLED}$ score (events per $100$ patient-years):\n- Score $0 \\mapsto 1.1$\n- Score $1 \\mapsto 1.0$\n- Score $2 \\mapsto 1.9$\n- Score $3 \\mapsto 3.7$\n- Score $4 \\mapsto 8.7$\n\nAssume that initiating a DOAC changes risks relative to no antithrombotic therapy as follows (apply multiplicatively to the baseline risks above):\n- Relative risk for ischemic stroke on DOAC: $r_{s} = 0.36$.\n- Relative risk for major bleeding on DOAC: $r_{b} = 1.25$.\n\nDefine the net clinical benefit as the difference between absolute ischemic strokes prevented and absolute major bleeds caused per $100$ patient-years, using equal weighting between an ischemic stroke event and a major bleeding event:\n$$\\text{Net clinical benefit} = \\text{ARR}_{\\text{stroke}} - \\text{ARI}_{\\text{bleed}},$$\nwhere $\\text{ARR}_{\\text{stroke}}$ is the absolute risk reduction in strokes and $\\text{ARI}_{\\text{bleed}}$ is the absolute risk increase in major bleeding after starting a DOAC.\n\nTasks:\n- Compute the patient’s $\\text{CHA}_2\\text{DS}_2\\text{-VASc}$ and $\\text{HAS-BLED}$ scores from the clinical data given.\n- Using the calibrations above, obtain the corresponding annual baseline risks (per $100$ patient-years) for ischemic stroke and for major bleeding without anticoagulation.\n- Apply the relative risks to estimate treated risks on a DOAC.\n- Compute the absolute risk reduction for stroke and the absolute risk increase for major bleeding, and then compute the net clinical benefit as defined.\n\nExpress the final net clinical benefit in events per $100$ patient-years, and round your final answer to three significant figures. Do not include the unit in your final boxed answer.",
            "solution": "The problem requires the calculation of the net clinical benefit of initiating a Direct Oral Anticoagulant (DOAC) for a patient with Atrial Fibrillation. This will be accomplished by following the prescribed sequence of tasks: calculating the patient's $\\text{CHA}_2\\text{DS}_2\\text{-VASc}$ and $\\text{HAS-BLED}$ scores, determining the baseline annual risks for ischemic stroke and major bleeding, calculating the risks on DOAC therapy, and finally computing the net clinical benefit.\n\nThe first step is to calculate the patient's $\\text{CHA}_2\\text{DS}_2\\text{-VASc}$ score based on the provided clinical data and scoring system. Let's denote the score as $S_{\\text{CHADS-VASc}}$. The patient is a $74$-year-old female with Congestive Heart Failure (CHF), hypertension, type $2$ diabetes mellitus, and prior myocardial infarction (vascular disease).\n\n- **C** (Congestive heart failure or left ventricular dysfunction): The patient has a history of CHF. This contributes $1$ point.\n- **H** (Hypertension): The patient has medically treated hypertension. This contributes $1$ point.\n- **A$_2$** (Age $\\geq 75$ years): The patient's age is $74$, which is not greater than or equal to $75$. This contributes $0$ points.\n- **D** (Diabetes mellitus): The patient has type $2$ diabetes mellitus. This contributes $1$ point.\n- **S$_2$** (Prior stroke, transient ischemic attack, or systemic embolism): The patient has no such history. This contributes $0$ points.\n- **V** (Vascular disease): The patient has a history of myocardial infarction. This contributes $1$ point.\n- **A** (Age $65$ to $74$ years): The patient's age is $74$, which falls in this range. This contributes $1$ point.\n- **Sc** (Sex category female): The patient is female. This contributes $1$ point.\n\nSumming the points, the total $\\text{CHA}_2\\text{DS}_2\\text{-VASc}$ score is:\n$$S_{\\text{CHADS-VASc}} = 1 (\\text{CHF}) + 1 (\\text{HTN}) + 0 (\\text{Age}\\geq 75) + 1 (\\text{DM}) + 0 (\\text{Stroke}) + 1 (\\text{Vascular}) + 1 (\\text{Age } 65-74) + 1 (\\text{Sex}) = 6$$\n\nThe second step is to calculate the patient's $\\text{HAS-BLED}$ score. Let's denote this score as $S_{\\text{HAS-BLED}}$.\n\n- **H** (Hypertension): The patient has treated hypertension. This contributes $1$ point.\n- **A** (Abnormal renal or liver function): The patient has chronic kidney disease with an estimated Glomerular Filtration Rate (eGFR) of $45\\ \\text{mL}\\cdot \\text{min}^{-1}\\cdot (1.73\\ \\text{m}^2)^{-1}$, which is less than $60\\ \\text{mL}\\cdot \\text{min}^{-1}\\cdot (1.73\\ \\text{m}^2)^{-1}$. This indicates abnormal renal function and contributes $1$ point. There is no mention of abnormal liver function.\n- **S** (Prior stroke): The patient has no history of stroke. This contributes $0$ points.\n- **B** (Bleeding history or predisposition): The patient has no prior major bleeding. This contributes $0$ points.\n- **L** (Labile INR): The patient is not on warfarin, so this does not apply. This contributes $0$ points.\n- **E** (Elderly, age $>65$ years): The patient's age is $74$, which is greater than $65$. This contributes $1$ point.\n- **D** (Drugs or alcohol): The patient has no concomitant nonsteroidal anti-inflammatory drugs or alcohol misuse specified. This contributes $0$ points.\n\nSumming the points, the total $\\text{HAS-BLED}$ score is:\n$$S_{\\text{HAS-BLED}} = 1 (\\text{HTN}) + 1 (\\text{Renal}) + 0 (\\text{Stroke}) + 0 (\\text{Bleeding}) + 0 (\\text{Labile INR}) + 1 (\\text{Elderly}) + 0 (\\text{Drugs/Alcohol}) = 3$$\n\nThe third step is to determine the baseline annual risks.\nUsing the provided calibration for the $\\text{CHA}_2\\text{DS}_2\\text{-VASc}$ score, a score of $S_{\\text{CHADS-VASc}} = 6$ corresponds to a baseline annual ischemic stroke risk, $R_{S,0}$, of $9.8$ events per $100$ patient-years.\n$$R_{S,0} = 9.8$$\nUsing the provided calibration for the $\\text{HAS-BLED}$ score, a score of $S_{\\text{HAS-BLED}} = 3$ corresponds to a baseline annual major bleeding risk, $R_{B,0}$, of $3.7$ events per $100$ patient-years.\n$$R_{B,0} = 3.7$$\n\nThe fourth step is to estimate the risks on DOAC therapy using the given relative risks: $r_s = 0.36$ for ischemic stroke and $r_b = 1.25$ for major bleeding.\nThe treated risk for ischemic stroke, $R_{S,\\text{DOAC}}$, is:\n$$R_{S,\\text{DOAC}} = R_{S,0} \\times r_s = 9.8 \\times 0.36 = 3.528$$\nThe treated risk for major bleeding, $R_{B,\\text{DOAC}}$, is:\n$$R_{B,\\text{DOAC}} = R_{B,0} \\times r_b = 3.7 \\times 1.25 = 4.625$$\nAll risks are in units of events per $100$ patient-years.\n\nThe final step is to compute the net clinical benefit (NCB). The NCB is defined as the absolute risk reduction in stroke ($\\text{ARR}_{\\text{stroke}}$) minus the absolute risk increase in major bleeding ($\\text{ARI}_{\\text{bleed}}$).\n\nThe absolute risk reduction for stroke is the difference between the baseline risk and the treated risk:\n$$\\text{ARR}_{\\text{stroke}} = R_{S,0} - R_{S,\\text{DOAC}} = R_{S,0} (1 - r_s)$$\n$$\\text{ARR}_{\\text{stroke}} = 9.8 - 3.528 = 6.272$$\n\nThe absolute risk increase for major bleeding is the difference between the treated risk and the baseline risk:\n$$\\text{ARI}_{\\text{bleed}} = R_{B,\\text{DOAC}} - R_{B,0} = R_{B,0} (r_b - 1)$$\n$$\\text{ARI}_{\\text{bleed}} = 4.625 - 3.7 = 0.925$$\n\nThe net clinical benefit is then:\n$$\\text{NCB} = \\text{ARR}_{\\text{stroke}} - \\text{ARI}_{\\text{bleed}}$$\n$$\\text{NCB} = 6.272 - 0.925 = 5.347$$\n\nThe problem asks to round the final answer to three significant figures. The calculated value is $5.347$. The first three significant figures are $5$, $3$, and $4$. The fourth figure is $7$, which is $\\geq 5$, so we round up the third figure.\n$$\\text{NCB} \\approx 5.35$$\nThe net clinical benefit is $5.35$ events per $100$ patient-years.",
            "answer": "$$\\boxed{5.35}$$"
        }
    ]
}